Application of a computer science analysis to a Non Hodgkin Lymphomas patients' dataset
暂无分享,去创建一个
[1] Giovanni Parmigiani,et al. On Optimal Screening Ages , 1993 .
[2] A. Hagenbeek,et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. G. Munford,et al. A Nearly Optimal Inspection Policy , 1972 .
[4] Stewart W. Wilson. Classifier Fitness Based on Accuracy , 1995, Evolutionary Computation.
[5] A. Hagenbeek,et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.
[6] Richard E. Barlow,et al. Optimum Checking Procedures , 1963 .
[7] A. Levis,et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. , 2008, Blood.
[8] J. Blay,et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. , 1998, Blood.
[9] Randy D Gascoyne,et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B Y Yeap,et al. Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Judy L. Smith,et al. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. , 2008, Journal of the National Comprehensive Cancer Network : JNCCN.
[12] M. Dimopoulos,et al. CEOP-21 Versus CEOP-14 Chemotherapy With or Without Rituximab for the First-Line Treatment of Patients With Aggressive Lymphomas: Results of the HE22A99 Trial of the Hellenic Cooperative Oncology Group , 2007, Cancer journal.
[13] N. Schmitz,et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.
[14] J. Poen,et al. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] J. Siedlecki,et al. Usefulness of real-time PCR in long-term follow-up of follicular lymphoma patients. , 2007, Acta biochimica Polonica.
[16] M. Ziepert,et al. Response Adapted Assignment of the Number of Chemotherapy Cycles for the Treatment of Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Is Not Justified: Results of the RICOVER-60 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). , 2007 .
[17] M. Pfreundschuh,et al. Treatment results of CHOP-21, CHOEP-21, MACOP-B and PMitCEBO with and without rituximab in young good-prognosis patients with aggressive lymphomas: Rituximab as an “equalizer” in the MInT (MABTHERA International Trial Group) study , 2005 .
[18] T. Barbui,et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. , 2007, Haematologica.
[19] P. Gaulard,et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.
[20] P. Gaulard,et al. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] A. Levis,et al. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an "Intergruppo Italiano Linfomi" randomized trial. , 2005, Haematologica.
[22] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[23] E. Oliva,et al. The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma , 2002, Bone Marrow Transplantation.
[24] V. Callea,et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. , 2005, Leukemia research.
[25] P. Gaulard,et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] Y. Shioyama,et al. Relapsed non-Hodgkin's lymphoma: detection and treatment. , 2000, Radiation medicine.
[27] R. Siebert,et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. , 2006, Blood.
[28] R. Marcus,et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. , 2005, Blood.
[29] P. Solal-Céligny. Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.
[30] A. Barrett,et al. Optimization of follow-up timing from study of patterns of first failure after primary treatment. An example from patients with NSCLC: a study of the REACT working group of ESTRO. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] G. Salles,et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). , 2006, Blood.